38 results on '"Roberta Agabio"'
Search Results
2. The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis
- Author
-
Julia Sinclair, David S. Baldwin, Lorenzo Leggio, Hugo J F Amaro, and Roberta Agabio
- Subjects
Agonist ,Baclofen ,medicine.medical_specialty ,Alcohol Drinking ,medicine.drug_class ,Cognitive Neuroscience ,Alcohol use disorder ,Anxiety ,Placebo ,03 medical and health sciences ,Behavioral Neuroscience ,chemistry.chemical_compound ,0302 clinical medicine ,Rating scale ,Internal medicine ,medicine ,Humans ,0501 psychology and cognitive sciences ,050102 behavioral science & comparative psychology ,business.industry ,05 social sciences ,medicine.disease ,Clinical trial ,Alcoholism ,Neuropsychology and Physiological Psychology ,chemistry ,GABA-B Receptor Agonists ,Meta-analysis ,medicine.symptom ,business ,030217 neurology & neurosurgery - Abstract
Given the high coexistence of anxiety symptoms in people with alcohol use disorder (AUD), we aimed to determine the influence of anxiety symptoms on outcomes in patients with AUD treated with the GABAB receptor agonist baclofen. A meta-analysis of 13 comparisons (published 2010-2020) including baseline and outcome data on alcohol consumption and anxiety after 12 weeks was undertaken. There were significantly higher rates of abstinent days in patients treated with baclofen compared to placebo (p = 0.004; high certainty evidence); specifically in those with higher baseline anxiety levels (p < 0.00001; high certainty evidence) compared to those with lower baseline anxiety levels (p = 0.20; moderate certainty evidence). The change in anxiety ratings over 12 weeks did not differ between those treated with baclofen or placebo (p = 0.84; moderate certainty evidence). This may be due to different anxiety constructs being measured by scales not validated in this patient group, or that anxiety is not a biobehavioral mechanism by which baclofen may reduce alcohol drinking. Given the prevalence of anxiety symptoms in AUD all these factors warrant further research.
- Published
- 2021
3. The validity of the state–trait anxiety inventory and the brief scale for anxiety in an inpatient sample with alcohol use disorder
- Author
-
Navan N. Shah, Breanne Hobden, Lorenzo Leggio, Roberta Agabio, Julia Sinclair, David S. Baldwin, and Melanie L. Schwandt
- Subjects
030508 substance abuse ,Medicine (miscellaneous) ,Alcohol use disorder ,Anxiety ,03 medical and health sciences ,0302 clinical medicine ,Positive predicative value ,medicine ,Humans ,030212 general & internal medicine ,Medical diagnosis ,Inpatients ,Receiver operating characteristic ,business.industry ,Alcohol dependence ,medicine.disease ,Anxiety Disorders ,United States ,Alcoholism ,Psychiatry and Mental health ,medicine.symptom ,0305 other medical science ,business ,State-Trait Anxiety Inventory ,Anxiety disorder ,Clinical psychology - Abstract
Background and AimsThe Brief Scale for Anxiety (BSA) and the State–Trait Anxiety Inventory Form Y‐2 (STAI‐Y‐2) are self‐report scales used to gauge anxiety symptoms in clinical settings. Co‐occuring anxiety is common in alcohol use disorder (AUD); however, no studies have assessed the validity of the BSA and STAI‐Y‐2 compared with a clinical diagnostic tool of anxiety in alcohol treatment programs. We aimed to examine the validity of the BSA and STAI‐Y‐2 to predict a clinical diagnosis of an anxiety disorder (via the Structured Clinical Interview for DSM [SCID]) in AUD patients.DesignParticipants were administered the BSA (n = 1005) on day 2 and the STAI‐Y‐2 (n = 483) between days 2 and 10 of the detoxification program. SCID‐based clinical diagnoses of AUD and anxiety were made approximately on day 10.Setting and participantsIndividuals seeking treatment for AUD admitted to an inpatient unit at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD, USA (n = 1010).MeasurementsInclusion criteria included a current diagnosis of alcohol dependence (AD) according to DSM‐IV‐TR or moderate to severe AUD according to DSM‐5‐RV, as well as available baseline BSA and/or STAI Y‐2 data. Empirical receiver operating characteristic (ROC) curves were generated using estimates of sensitivity, 1‐specificity and positive and negative predictive values for each cut‐point to determine the accuracy of scale outcomes in relation to SCID diagnoses.FindingsThe BSA demonstrated low accuracy relative to a clinical diagnosis of anxiety with an area under the curve (AUC) of 0.67 at the optimal cut‐point of ≥ 10. The STAI‐Y‐2 had moderate accuracy relative to a clinical diagnosis of anxiety with an AUC of 0.70 at the optimal cut‐point of ≥ 51. The accuracy of the STAI‐Y‐2 increased (AUC = 0.74) when excluding post‐traumatic stress disorder and obsessive–compulsive disorder from anxiety disorder classification.ConclusionsUse of the Brief Scale for Anxiety (BSA) and/or State–Trait Anxiety Inventory Form Y‐2 (STAI‐Y‐2) does not appear to be a reliable substitute for clinical diagnoses of anxiety disorder among inpatients with alcohol use disorder. The BSA and STAI‐Y‐2 could serve as a screening tool to reject the presence of anxiety disorders rather than for detecting an anxiety disorder.
- Published
- 2021
4. Gender Differences among Sardinians with Alcohol Use Disorder
- Author
-
Luigi Minerba, Roberta Agabio, Gian Luigi Gessa, Flavia Franconi, and Claudia Pisanu
- Subjects
women’s needs ,Medical treatment ,business.industry ,birth cohort effects ,General Medicine ,Alcohol use disorder ,alcohol use disorder ,medicine.disease ,Sardinia ,Article ,Cultural background ,Spouse ,gender differences ,mental disorders ,medicine ,Anxiety ,Medicine ,Substance use ,medicine.symptom ,business ,Depression (differential diagnoses) ,Demography ,access to treatment - Abstract
Sardinia is an Italian island in the Mediterranean characterized by secular isolation and the singular genetic characteristics of its inhabitants. Findings obtained in populations with diverse genetic make-up and cultural background indicate gender differences and/or similarities in drinking characteristics of patients with alcohol use disorder (AUD). Knowledge of these characteristics in AUD patients is useful to improve access to treatments. This paper investigated the drinking characteristics of 66 female and 282 male outpatients with AUD, born from 1937 to 1991, living in Sardinia, and compared their characteristics with those of AUD patients living in other countries. Most Sardinian patients were men, approximately 3 years younger than women, women consumed lower amounts of alcohol than men but did not differ from men in the severity of AUD. Men were more often single than women, while a higher proportion of women reported that their mother or spouse was affected by AUD. Anxiety and depression were more prevalent among women while a higher proportion of men were affected by substance use disorders. Women were older than men at the age of first drink, regular drinking, and onset of AUD, and progressed faster than men from regular use to AUD onset. Women did not differ from men in age at first request for care, and in the lapse from AUD onset to first request for care. Women and men waited for more than 8 and 9 years, respectively, before receiving medical treatment. Gender differences progressively decreased among younger patients. Although the scarce number of women in some cohorts limits the strength of these findings, drinking characteristics of Sardinian patients did not vary significantly from those of AUD patients living in other countries. These results suggest that the number of Sardinian women with AUD is increasing and services for treatment of AUD should (a) consider women’s specific needs, and (b) realize effective policies to reduce latency prior to accessing medical treatment for both men and women with AUD.
- Published
- 2021
5. Alcohol Consumption Is a Modifiable Risk Factor for Breast Cancer:: Are Women Aware of This Relationship?
- Author
-
Elena Massa, Claudia Sardu, Monica Deiana, Clelia Madeddu, Paolo Contu, Sofia Cosentino, Alessandra Mereu, Carola Politi, Roberta Agabio, and Julia Sinclair
- Subjects
Male ,Alcohol Drinking ,MEDLINE ,Breast Neoplasms ,Context (language use) ,Unit of alcohol ,03 medical and health sciences ,Breast cancer screening ,0302 clinical medicine ,Breast cancer ,Risk Factors ,Environmental health ,medicine ,Humans ,Mass Screening ,Breast screening ,030212 general & internal medicine ,Risk factor ,Early Detection of Cancer ,medicine.diagnostic_test ,business.industry ,General Medicine ,medicine.disease ,030220 oncology & carcinogenesis ,Female ,business ,Alcohol consumption - Abstract
Aims Despite alcohol consumption being a dose-dependent risk factor for breast cancer, a recent study conducted in the UK found Methods The questionnaire used by the UK study was translated into Italian, slightly modified for the Italian context, validated and submitted to a sample of Italian women. Results Overall 507 women were interviewed. Among them, 160 were classified as breast cancer screening attenders (SG), 44 as symptomatic breast clinic attenders (CAG) and 303 as non-screening group (NSG). Alcohol was correctly identified as a risk factor for breast cancer by 16.9, 11.4 and 14.9% of participants of SG, CAG and NSG, respectively without differences between the three groups. Despite the methodological differences, the rates of participants who correctly identified alcohol as a risk factor among women attending breast screening programmes were surprisingly similar between the study conducted in UK (15.7%) and the present study (16.9%). Conclusion The results of the present study confirm the limited awareness of the relationship between alcohol consumption and risk of developing breast cancer among women and suggest the urgent need to conduct proper awareness-raising campaigns to counter this in the Italian female population.
- Published
- 2021
6. Baclofen and other GABA-B agonists for alcohol use disorders: An international perspective
- Author
-
H.J. Aubin, Roberta Agabio, Giovanni Addolorato, and B. Rolland
- Subjects
medicine.medical_specialty ,business.industry ,Sodium Oxybate ,Alcohol ,Alcohol use disorder ,medicine.disease ,GABA B Agonists ,chemistry.chemical_compound ,Baclofen ,Pharmacotherapy ,nervous system ,chemistry ,medicine ,In patient ,Medical prescription ,business ,Psychiatry - Abstract
The poor implementation of alcohol use disorder treatment programs has been well documented in many countries. Among the barriers have been identified in health professionals and patients, lack of awareness about existing medications and perceived lack of efficacy seem to deter physicians from offering pharmacotherapy to their patients. Indeed, existing registered medications are only modestly effective. Therefore, there is an urgent need to develop more effective treatments in this area, ideally targeting new mechanisms of action. The efficacy of GABAB agonists has been explored for some time, as they are believed to reduce alcohol craving, possibly through alcohol mimicking effects. In particular, two drugs, both decades-long marketed for other purposes, have been tested: baclofen and sodium oxybate. Sodium oxybate is approved for the treatment of alcohol use disorder in several countries, and efforts or currently been made to obtain an approval at the European level. This medication has showed medium to large treatment effects in patients with severe alcohol dependence [1] . Baclofen has recently been labeled for the treatment of alcohol use disorder in France, the only country so far having officially approved baclofen in this indication. Off-label Baclofen prescription for alcohol use disorder substantially increased a decade ago, leading to a regulatory recognition named a “temporary recommendation for use” in 2014, and eventually a full approval in 2018, despite the lack of consistent evidence of efficacy [2] . At the international level, a number of experts meeting in Cagliari succeeded in publishing a consensual statement regarding baclofen for the treatment of alcohol use disorder [3] . The aim of this session is to provide a scientific and historical background on the development of GABA-B agonists in alcohol use disorders, state of the art regarding baclofen efficacy and safety, and to elucidate the singularity of the French experience with baclofen that eventually permitted it's official approval.
- Published
- 2019
7. Sex differences in the response to opioids for pain relief: A systematic review and meta-analysis
- Author
-
Sergio Mameli, Roberta Agabio, Claudia Pisanu, Flavia Franconi, Lorenzo Leggio, Ilaria Campesi, Giovanni Maria Pisanu, and Gian Luigi Gessa
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Visual analogue scale ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Pain Management ,Medical prescription ,Pharmacology ,business.industry ,Chronic pain ,Cancer Pain ,medicine.disease ,Clinical trial ,Analgesics, Opioid ,030104 developmental biology ,Opioid ,Strictly standardized mean difference ,030220 oncology & carcinogenesis ,Meta-analysis ,Chronic Pain ,Cancer pain ,business ,medicine.drug - Abstract
There are conflicting results about sex differences in the response to opioids for pain control and the role of potential influencing factors of these differences has not been investigated. We meta-analyzed differences and similarities between men and women in opioid response for pain control and investigated the potential influence of baseline pain intensity, age, body weight, and other factors in these findings. PubMed, Scopus, and Cochrane CENTRAL were searched through January 15, 2019, for clinical studies in which opioids were administered for pain control. We included clinical studies in which (a) opioids were used to treat acute or chronic pain, (b) the response to opioids was broken down for men and women, and (c) the response to opioids was reported as (i) difference between baseline and final Visual Analog Scale of Pain Intensity (VASPI) score 30 min after opioid administration (Delta-VASPI at 30′), or daily dose of opioids (ii) self-administered by patients (patient-controlled analgesia PCA), or (iii) administered by physicians. Risk of bias was evaluated using ROBINS-I and the overall quality of evidence for primary outcomes was evaluated using the GRADE system. Globally, we included 40 comparisons (6794 patients). Regarding acute pain, we found moderate quality of evidence that women and men do not differ in their response to opioids 30 min after their administration [Delta-VASPI at 30′: mean difference, MD = 0.42 (−0.07; 0.91)]. We also found moderate quality of evidence that women self-administer lower daily amounts of opioids [daily PCA: standardized mean difference, SMD = −0.30 (−0.41; −0.18)]. Regarding chronic pain, we found low quality of evidence that women receive lower daily doses for non-cancer pain [MD = −36.42 (−57.86; –14.99)]. By contrast, we found very low quality of evidence that women and men do not differ in the daily dose of opioids for cancer pain [MD = −16.09 (−40.13; 7.94)]. Age, comorbid mental disorders, type of administration, type of opioids, type of patients, and body weight significantly modified these results. In conclusion, the results of the present meta-analysis suggest that men and women may differ in the response to opioids for pain relief, but these differences as well as similarities are significantly influenced by factors like age and comorbid mental disorders. However, the role of these factors is not usually evaluated in the prescription of opioids for pain control. There is an urgent need to conduct clinical trials on the use of opioid medications for pain, in which information about all possible influencing factors are provided and broken down for men and women.
- Published
- 2019
8. The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective
- Author
-
Renaud de Beaurepaire, Julia M. A. Sinclair, Mathis Heydtmann, Giovanni Addolorato, Henri-Jean Aubin, Esther M. Beraha, Fabio Caputo, Jonathan D. Chick, Patrick de La Selle, Nicolas Franchitto, James C. Garbutt, Paul S. Haber, Philippe Jaury, Anne R. Lingford-Hughes, Kirsten C. Morley, Christian A. Müller, Lynn Owens, Adam Pastor, Louise M. Paterson, Fanny Pélissier, Benjamin Rolland, Amanda Stafford, Andrew Thompson, Wim van den Brink, Lorenzo Leggio, Roberta Agabio, and Medical Research Council (MRC)
- Subjects
safety ,medicine.medical_specialty ,WITHDRAWAL SYNDROME ,lcsh:RC435-571 ,Population ,efficacy ,Placebo-controlled study ,baclofen ,Alcohol use disorder ,HIGH-DOSE BACLOFEN ,alcohol use disorder ,PLACEBO-CONTROLLED TRIAL ,law.invention ,NO ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,POSITIVE ALLOSTERIC MODULATOR ,Randomized controlled trial ,law ,lcsh:Psychiatry ,mental disorders ,Medicine ,Dosing ,Medical prescription ,education ,Intensive care medicine ,DEPENDENT PATIENTS ,SUBSTANCE USE ,Psychiatry ,education.field_of_study ,Science & Technology ,business.industry ,Maintenance dose ,GABA-B ,PRELIMINARY DOUBLE-BLIND ,medicine.disease ,030227 psychiatry ,Psychiatry and Mental health ,Baclofen ,chemistry ,B RECEPTOR AGONIST ,GABA-B, baclofen, alcohol use disorder, efficacy, safety ,business ,Life Sciences & Biomedicine ,030217 neurology & neurosurgery ,GABA(B) RECEPTOR ,PHARMACOLOGICAL-TREATMENT - Abstract
Alcohol use disorder (AUD) is a brain disorder associated with high rates of mortality and morbidity worldwide. Baclofen, a selective gamma-aminobutyric acid-B (GABA-B) receptor agonist, has emerged as a promising drug for AUD. The use of this drug remains controversial, in part due to uncertainty regarding dosing and efficacy, alongside concerns about safety. To date there have been 15 randomized controlled trials (RCTs) investigating the use of baclofen in AUD; three using doses over 100 mg/day. Two additional RCTs have been completed but have not yet been published. Most trials used fixed dosing of 30-80 mg/day. The other approach involved titration until the desired clinical effect was achieved, or unwanted effects emerged. The maintenance dose varies widely from 30 to more than 300 mg/day. Baclofen may be particularly advantageous in those with liver disease, due to its limited hepatic metabolism and safe profile in this population. Patients should be informed that the use of baclofen for AUD is as an "off-label" prescription, that no optimal fixed dose has been established, and that existing clinical evidence on efficacy is inconsistent. Baclofen therapy requires careful medical monitoring due to safety considerations, particularly at higher doses and in those with comorbid physical and/or psychiatric conditions. Baclofen is mostly used in some European countries and Australia, and in particular, for patients who have not benefitted from the currently used and approved medications for AUD.
- Published
- 2019
9. Baclofen in the Treatment of Alcohol Use Disorder
- Author
-
Renaud de Beaurepaire, Roberta Agabio, and M. Heydtmann
- Subjects
medicine.medical_specialty ,business.industry ,Addiction ,media_common.quotation_subject ,Alcohol use disorder ,medicine.disease ,Mental health ,chemistry.chemical_compound ,Liver disease ,Baclofen ,chemistry ,Alcohol withdrawal syndrome ,medicine ,business ,Psychiatry ,media_common - Published
- 2019
10. The Cagliari Statement on baclofen for the treatment of alcohol use disorder: An International Consensus
- Author
-
Lorenzo Leggio, Roberta Agabio, and Julia Sinclair
- Subjects
medicine.medical_specialty ,business.industry ,medicine.drug_class ,Muscle relaxant ,Alcohol use disorder ,medicine.disease ,Placebo ,law.invention ,chemistry.chemical_compound ,Baclofen ,nervous system ,Randomized controlled trial ,chemistry ,law ,Intervention (counseling) ,mental disorders ,Risk of mortality ,Medicine ,Anxiety ,medicine.symptom ,business ,Psychiatry - Abstract
Alcohol Use Disorder (AUD) is a common mental disorder with severe medical, psychological and social consequences [1] . AUD leads up to 3- and 4-fold increases in the risk of mortality in men and women, respectively [2] . Nevertheless, less than 10% of people with AUD seek and receive treatment for their disorder and less than 4% receive any pharmacological intervention [3] . The identification of new medications is crucial to increase the number of people with AUD who receive effective treatment. Baclofen, a GABAB receptor agonist approved for clinical use as a muscle relaxant, has emerged as a promising drug for AUD [4] . Preclinical studies have provided consistent evidence that baclofen administration dose-dependently reduces alcohol consumption in validated animal models of AUD [5] . On the other hand, clinical studies have yielded less consistent results [6] . Some randomized controlled trials (RCTs) found that AUD patients treated with baclofen significantly reduced alcohol consumption compared to patients treated with placebo, whereas other RCTs found no differences between AUD patients treated with baclofen or placebo [6] . In addition, recent meta-analyses report there is insufficient evidence of effectiveness to support the use of baclofen to treat AUD [7] , [8] , [9] , [10] . Several methodological differences among these RCTs may have contributed to these contrasting results, including (i) the daily dose of baclofen (ranging from 30 to 300 mg), (ii) prescribing regimes (fixed doses or titration until the desired clinical effect was achieved), and (iii) presence/absence of comorbid medical (e.g. liver disease) or psychiatric diseases (e.g. anxiety disorders) [6] , [11] . Nevertheless, baclofen is used off-label to treat AUD in several countries, and in France baclofen was officially approved for AUD treatment in October 2018 [6] . In May 2018, during the GABAB Receptor Conference, held in Cagliari, Italy, a group of international experts in the clinical use of baclofen for AUD met and combined their expertise to provide concise and well-balanced information regarding this controversial topic. This group included 26 researchers and physicians who had contributed to the majority of RCTs (both positive and negative) on baclofen and AUD as well as studies focused on the side effects of baclofen in patients with AUD. A modified Delphi method was used. Each statement was discussed, modified, and rated until consensus was reached by the entire group. The final draft included 18 statements and was recently published as “the Cagliari Statement” in Lancet Psychiatry [12] . This Consensus paper is intended as a helpful tool for clinicians deciding whether or not prescribe baclofen off-label to their patients with AUD and to researchers planning investigations with baclofen. The Cagliari Statement may be particularly useful clinicians in France, where baclofen has been officially approved for AUD treatment [6] .
- Published
- 2019
11. Baclofen in the Treatment of Patients With Alcohol Use Disorder and Other Mental Health Disorders
- Author
-
Lorenzo Leggio and Roberta Agabio
- Subjects
medicine.medical_specialty ,lcsh:RC435-571 ,medicine.drug_class ,Mini Review ,baclofen ,Alcohol use disorder ,alcohol use disorder ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,lcsh:Psychiatry ,GABAB ,mental disorders ,medicine ,Psychiatry ,business.industry ,Therapeutic effect ,Muscle relaxant ,medicine.disease ,anxiety ,Mental health ,mood disorders ,030227 psychiatry ,3. Good health ,Psychiatry and Mental health ,Baclofen ,chemistry ,Mood disorders ,nervous system ,Anxiety ,medicine.symptom ,mental health disorders ,business ,Psychosocial ,030217 neurology & neurosurgery - Abstract
A limited number of medications are approved to treat Alcohol Use Disorder (AUD). Furthermore, the magnitude of their therapeutic effect is relatively modest, suggesting the potential for subtypes of patients who respond to a specific medication. The use of these medications is also limited in clinical practice by a series of contraindications such as medical comorbidities and/or concurrent use of other medications. In recent years, animal and human studies have been conducted to evaluate the efficacy of baclofen, a GABAB receptor agonist approved for clinical use as a muscle relaxant, in the treatment of AUD. However, these studies have yielded contrasting results. Despite this discrepancy, baclofen is often used off-label to treat AUD, especially in some European countries and Australia. Recently, several factors have been considered to try to shed light on the potential reasons and mechanisms underlying the inconsistent results obtained until now. The presence of a psychiatric comorbidity may be amongst the abovementioned factors playing a role in explaining different responses to baclofen treatment in terms of alcohol drinking outcomes. Therefore, the aim here was to conduct a narrative review of the scientific literature related to the use of baclofen in AUD, both in patients with and without concomitant psychiatric disorders. All clinical studies (randomized and controlled, open-label, retrospective, human laboratory studies, and case reports) were analyzed and discussed, bearing in mind other potential factors that may have influenced baclofen response, including dose administered, severity of AUD, use of other psychosocial therapies, and the presence of physical disorders. This review indicates that the most frequent psychiatric comorbidities in patients affected by AUD undergoing baclofen treatment are anxiety and mood disorders. Unfortunately, no definitive conclusions can be drawn due to the lack of specific analyses on whether baclofen efficacy is different in AUD patients with comorbid psychiatric disorders vs. those without. Therefore, it will be critical that psychiatric comorbidities are considered in the planning of future studies and in the analysis of the data, with the ultimate goal of understanding whether subtypes of AUD patients may respond best to baclofen.
- Published
- 2018
12. Diagnosis and treatment of acute alcohol intoxication and alcohol withdrawal syndrome: position paper of the Italian Society on Alcohol
- Author
-
Gianni Testino, S Arico, Giovanni Greco, Doda Renzetti, Paolo Cimarosti, Michele Parisi, Maria Francesca Amendola, Livia Maccio, Pierluigi Allosio, Cristina Meneguzzi, Teo Vignoli, Fabio Caputo, Patrizia Balbinot, Roberta Agabio, Emanuele Scafato, Valentino Patussi, Vincenzo Palmieri, Tiziana Fanucchi, Raffaella Rossin, Valeria Zavan, and Davide Mioni
- Subjects
medicine.medical_specialty ,Acute alcohol intoxication ,Acute alcohol intoxication, Alcohol withdrawal syndrome, Pharmacological treatment ,Alcohol use disorder ,030204 cardiovascular system & hematology ,Tiapride ,NO ,law.invention ,Alcohol withdrawal syndrome ,03 medical and health sciences ,chemistry.chemical_compound ,Benzodiazepines ,0302 clinical medicine ,law ,Clomethiazole ,Internal Medicine ,medicine ,Humans ,030212 general & internal medicine ,Propofol ,Delirium tremens ,business.industry ,medicine.disease ,Tiapride Hydrochloride ,Intensive care unit ,Substance Withdrawal Syndrome ,chemistry ,Phenobarbital ,Emergency medicine ,Emergency Medicine ,Anticonvulsants ,business ,Sodium Oxybate ,Pharmacological treatment ,Alcoholic Intoxication ,Chlormethiazole ,medicine.drug - Abstract
The chronic use of alcohol can lead to the onset of an alcohol use disorder (AUD). About 50% of subjects with an AUD may develop alcohol withdrawal syndrome (AWS) when they reduce or discontinue their alcohol consumption and, in 3-5% of them, convulsions and delirium tremens (DTs), representing life-threatening complications, may occur. Unfortunately, few physicians are adequately trained in identifying and treating AWS. The Italian Society on Alcohol has, therefore, implemented a task force of specialists to draw up recommendations for the treatment of AWS with the following main results: (1) while mild AWS may not require treatment, moderate and severe AWS need to be pharmacologically treated; (2) out-patient treatment is appropriate in patients with mild or moderate AWS, while patients with severe AWS need to be treated as in-patients; (3) benzodiazepines, BDZs are the "gold standard" for the treatment of AWS and DTs; (4) alpha-2-agonists, beta-blockers, and neuroleptics may be used in association when BDZs do not completely resolve specific persisting symptoms of AWS; (5) in the case of a refractory form of DTs, the use of anaesthetic drugs (propofol and phenobarbital) in an intensive care unit is appropriate; (6) alternatively to BDZs, sodium oxybate, clomethiazole, and tiapride approved in some European Countries for the treatment of AWS may be employed for the treatment of moderate AWS; (7) anti-convulsants are not sufficient to suppress AWS, and they may be used only in association with BDZs for the treatment of refractory forms of convulsions in the course of AWS.
- Published
- 2018
13. Baclofen for the treatment of alcohol use disroder: the Cagliari Statement
- Author
-
Giovanni Addolorato, Renaud de Beaurepaire, Benjamin Rolland, Fanny Pelissier, Wim van den Brink, Adam Pastor, Jonathan Chick, Andrew Thompson, Christian Müller, Fabio Caputo, Philippe Jaury, Lynn Owens, Lorenzo Leggio, Esther M. Beraha, Roberta Agabio, Patrick de La Selle, Paul S. Haber, Anne Lingford-Hughes, Amanda Stafford, Julia Sinclair, Kirsten C. Morley, James C. Garbutt, Nicolas Franchitto, Henri-Jean Aubin, Louise M. Paterson, M. Heydtmann, Adult Psychiatry, and ANS - Compulsivity, Impulsivity & Attention
- Subjects
Psychiatry ,medicine.medical_specialty ,Science & Technology ,business.industry ,Statement (logic) ,MORTALITY ,MEDLINE ,Alcohol use disorder ,medicine.disease ,030227 psychiatry ,NO ,03 medical and health sciences ,Psychiatry and Mental health ,chemistry.chemical_compound ,0302 clinical medicine ,Baclofen ,chemistry ,medicine ,business ,Life Sciences & Biomedicine ,030217 neurology & neurosurgery ,Biological Psychiatry - Published
- 2018
14. HIV and alcohol use disorder: we cannot ignore the elephant in the room
- Author
-
Roberta Agabio and Lorenzo Leggio
- Subjects
medicine.medical_specialty ,Infectious Diseases ,Epidemiology ,business.industry ,Virology ,Immunology ,medicine ,Human immunodeficiency virus (HIV) ,Alcohol use disorder ,Psychiatry ,medicine.disease ,medicine.disease_cause ,business - Published
- 2019
15. Efficacy of Medications Approved for the Treatment of Alcohol Dependence and Alcohol Withdrawal Syndrome in Female Patients: A Descriptive Review
- Author
-
Roberta Agabio, Antonio Preti, Flavia Franconi, Gian Luigi Gessa, and Pier Paolo Pani
- Subjects
Male ,medicine.medical_specialty ,Health (social science) ,Taurine ,Acamprosate ,Medicine (miscellaneous) ,Naltrexone ,Alcohol Withdrawal Delirium ,Benzodiazepines ,03 medical and health sciences ,Sex Factors ,0302 clinical medicine ,Internal medicine ,Disulfiram ,medicine ,Humans ,030212 general & internal medicine ,Nalmefene ,business.industry ,Alcohol dependence ,medicine.disease ,Alcoholism ,Psychiatry and Mental health ,Treatment Outcome ,Alcohol withdrawal syndrome ,Anesthesia ,Alcohol Deterrents ,Anticonvulsants ,Female ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
The aim of this study was to evaluate whether the number of women recruited for studies to establish the efficacy of medications approved for treatment of alcohol dependence (AD) and of alcohol withdrawal syndrome (AWS) is sufficient to reveal possible gender differences in the response to these medications and in suggesting the use of different doses in female patients. Our results show that the rates of women recruited for studies evaluating the efficacy of disulfiram (1%), benzodiazepines (3%), and anticonvulsants (13%) were too low to establish possible gender differences. The rates of women recruited for studies evaluating the efficacy of acamprosate (22%), naltrexone (23%), and nalmefene (30%) were higher and allowed evaluation of data obtained for female patients. Women receive medications for treatment of AD and/or AWS for which efficacy has been demonstrated in studies in which men were more largely represented.
- Published
- 2015
16. Oxytocin nasal spray in fibromyalgic patients
- Author
-
Mauro Giovanni Carta, Giuseppina Trincas, Maria Rosaria Melis, A Marchi, A. Pili, Sergio Mameli, Roberta Agabio, M. Carboni, G. M. Pisanu, Luigi Minerba, and Salvatore Sardo
- Subjects
Pain disorder ,medicine.medical_specialty ,Visual analogue scale ,business.industry ,medicine.medical_treatment ,Immunology ,medicine.disease ,Placebo ,law.invention ,Mood ,Rheumatology ,Randomized controlled trial ,Nasal spray ,law ,Fibromyalgia ,medicine ,Physical therapy ,Immunology and Allergy ,Anxiety ,medicine.symptom ,business - Abstract
Fibromyalgia is a pain disorder associated with frequent comorbid mood, anxiety, and sleep disorders. Despite the frequent use of a complex, poly-drug pharmacotherapy, treatment for fibromyalgia is of limited efficacy. Oxytocin has been reported to reduce the severity of pain, anxiety, and depression, and improve the quality of sleep, suggesting that it may be useful to treat fibromyalgia. To evaluate this hypothesis, 14 women affected by fibromyalgia and comorbid disorders, assuming a complex pharmacotherapy, were enrolled in a double-blind, crossover, randomized trial to receive oxytocin and placebo nasal spray daily for 3 weeks for each treatment. Order of treatment (placebo-oxytocin or oxytocin-placebo) was randomly assigned. Patients were visited once a week. At each visit, the following instruments were administered: an adverse drug reaction record card, Visual Analog Scale of Pain Intensity, Spielberger State Anxiety Inventory, Zung Self-rating Depression Scale, and SF-12. Women self-registered painkiller assumption, pain severity, and quality of sleep in a diary. Unlikely, oxytocin nasal spray (80 IU a day) did not induce positive therapeutic effects but resulted to be safe, devoid of toxicity, and easy to handle.
- Published
- 2014
17. Sex Differences in Alcohol Use Disorder
- Author
-
Claudia Pisanu, Gian Luigi Gessa, Roberta Agabio, and Flavia Franconi
- Subjects
medicine.medical_specialty ,Alcohol Drinking ,Special needs ,Alcohol use disorder ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,mental disorders ,Drug Discovery ,Female patient ,Epidemiology ,medicine ,Animals ,Humans ,Psychiatry ,Socioeconomic status ,Pharmacology ,Sex Characteristics ,business.industry ,Organic Chemistry ,medicine.disease ,030227 psychiatry ,Molecular Medicine ,business ,Alcohol consumption ,Alcohol-Related Disorders ,030217 neurology & neurosurgery - Abstract
Background: Alcohol use disorder (AUD) is a common and disabling mental disorder associated with a significant burden of medical consequences and high socioeconomic costs. Although a growing number of studies support the existence of sex differences in several aspects of alcohol consumption and AUD, the majority of investigations have been conducted in men. Objective: This article was aimed at reviewing sex differences in AUD, focusing on epidemiology, neurobiology, pharmacokinetics, susceptibility to medical consequences, and treatment. Results: Although AUD is more prevalent in men, the number of women with AUD is rapidly increasing, especially in adolescents. Women show a higher vulnerability to medical consequences induced by alcohol consumption, including alcohol-related liver disease, cardiomyopathy, and breast cancer. This observation is only partly explained by the sex differences observed in the pharmacokinetics of alcohol. Women also show an accelerated progression from the first use of alcohol to the onset of AUD and appear to be at higher risk of alcohol–medication interactions. Although AUD women are less likely to seek treatment than men, they achieve better results through dedicated programs taking into account the special needs of female patients. However, findings on the efficacy and safety of medications used to treat AUD mostly come from studies in which women were largely underrepresented. Conclusion: The sex differences observed suggest the urgent need to conduct studies recruiting adequate numbers of female subjects, to increase knowledge of sex differences in AUD, and to develop personalized and evidence-based approaches of prevention and treatment of AUD in women.
- Published
- 2016
18. Targeting the GABAB Receptor for the Treatment of Alcohol Use Disorder
- Author
-
Giovanni Addolorato, Giancarlo Colombo, Kimberly A. Leite-Morris, and Roberta Agabio
- Subjects
Agonist ,medicine.drug_class ,business.industry ,musculoskeletal, neural, and ocular physiology ,Alcohol ,Craving ,Alcohol use disorder ,GABAB receptor ,Pharmacology ,medicine.disease ,030227 psychiatry ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Therapeutic index ,Baclofen ,nervous system ,chemistry ,mental disorders ,medicine ,medicine.symptom ,Receptor ,business ,030217 neurology & neurosurgery - Abstract
Accumulating lines of experimental and clinical evidence suggest that the prototypic, orthosteric GABA type B (GABAB) receptor agonist, baclofen, may possess therapeutic potential for treatment of alcohol use disorder (AUD). At preclinical level, acute or repeated treatment with nonsedative doses of baclofen has repeatedly been reported to suppress several alcohol-motivated behaviors, including alcohol drinking, in rats and mice. At clinical level, administration of doses of baclofen ranging from low to extremely high doses has been found to suppress alcohol consumption, craving for alcohol, and alcohol withdrawal signs and symptoms in patients affected by AUD, confirming that baclofen may represent a promising option for treatment of AUD. A more recent avenue of research is represented by generalization of baclofen effects to the positive allosteric modulators of the GABAB receptor: preclinical data collected to date suggest that these compounds reproduce, with a much higher therapeutic index, several suppressing effects of baclofen on alcohol-motivated behaviors.
- Published
- 2016
19. Oxytocin Nasal Spray in the Treatment of Binge Eating Disorder and Obesity: A Pilot, Randomized, Double-Blind Trial
- Author
-
Gian Luigi Gessa, Roberta Agabio, Raffaele Deidda, Maria Rosaria Melis, Silvia Mercuro, Olga Curreli, Elisa Tronci, Angelo Restivo, Anna Maria Giulia Farci, and Romina Naitana
- Subjects
medicine.medical_specialty ,Binge eating ,business.industry ,medicine.medical_treatment ,030209 endocrinology & metabolism ,Craving ,General Medicine ,medicine.disease ,Placebo ,Obesity ,03 medical and health sciences ,0302 clinical medicine ,Oxytocin ,Nasal spray ,Binge-eating disorder ,Internal medicine ,Medicine ,Anxiety ,medicine.symptom ,business ,Psychiatry ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Background Preclinical studies suggest that the neuropeptide oxytocin reduces food intake and body weight, but only a few clinical studies have investigated the translatability of these findings in humans. The present study investigated the safety and efficacy of oxytocin nasal spray in patients affected by binge eating disorder and obesity. Methods Seventeen outpatients affected by binge eating disorder and obesity participated in a 8 week double-blind trial and received oxytocin (n=8; 24 IU, four times a day, 20 min before each of three meals and before going to bed) or placebo (n=9) with an energy-restricted diet. Primary outcomes included adverse events and the number of binge eating episodes per week. Secondary measures included body weight, BMI, severity of BED, craving for food, quality of sleep, quality of life, anxiety, and depressive symptoms. Results One patient of oxytocin group discontinued prematurely the trial before the first post-randomization efficacy measure. Among the other 16 participants, 13 (81.2%) completed the trial, and 3 (18.8%) discontinued [3 in the oxytocin group; 0 in the placebo group (p=0.0625, Fisher’s exact test)]. No significant difference between groups was found in any outcome evaluated. Patients of the placebo group performed slightly better than patients of the oxytocin group in some secondary outcomes, but these differences were not significant. Conclusion Oxytocin nasal spray resulted to be safe, including in women of childbearing age but did not significantly reduce the number of binge eating episodes per week in outpatients affected by binge eating disorder and obesity. These findings are discussed in light of the human oxytocin literature.
- Published
- 2016
20. Use of the Screening Suggested by the National Institute on Alcohol Abuse and Alcoholism and of a Newly Derived Tool for the Detection of Unhealthy Alcohol Drinkers Among Surgical Patients
- Author
-
Gabriele Finco, Paolo Contu, Giorgio Bedogni, Andrea Montisci, Gian Luigi Gessa, A Marchi, and Roberta Agabio
- Subjects
Adult ,Male ,medicine.medical_specialty ,Health (social science) ,Adolescent ,Alcohol Drinking ,Alcohol abuse ,Poison control ,Audit ,Toxicology ,Suicide prevention ,Occupational safety and health ,Young Adult ,Surveys and Questionnaires ,Preoperative Care ,Injury prevention ,Humans ,Medicine ,Psychiatry ,Aged ,Aged, 80 and over ,Alcohol Use Disorders Identification Test ,business.industry ,Human factors and ergonomics ,Middle Aged ,medicine.disease ,United States ,Surgery ,Alcoholism ,Psychiatry and Mental health ,Italy ,Female ,business ,National Institute on Alcohol Abuse and Alcoholism (U.S.) - Abstract
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) has developed a two-question tool for the detection of unhealthy drinking (NIAAA-2Q) that investigates excessive alcohol consumption per single occasion. NIAAA-2Q can be commuted into a four-question tool (NIAAA-4Q) by the addition of two questions aimed at investigating excessive weekly alcohol intake. NIAAA-2Q and NIAAA-4Q may prove useful in busy settings such as an anesthesiological environment. However, to date, no study has evaluated their efficacy in a surgical setting. The purpose of this study was to evaluate the accuracy of NIAAA-2Q and NIAAA-4Q in detecting unhealthy drinking among surgical patients using the more complex Alcohol Use Disorders Identification Test (AUDIT) comprising 10 questions as the criterion method.NIAAA-4Q and AUDIT were administered to 200 surgical patients by three anesthetists.A total of 23.5%, 12.5%, and 28.5% surgical patients were unhealthy drinkers according to AUDIT, NIAAA-2Q, and NIAAA-4Q, respectively. NIAAA-2Q negative and positive predictive values were 0.78 and 0.36, respectively, and positive and negative likelihood ratios were 1.80 and 0.90, respectively. NIAAA-4Q negative and positive predictive values were 0.93 and 0.65, respectively, and positive and negative likelihood ratios were 6.00 and 0.24, respectively.NIAAA-4Q demonstrated a better satisfactory agreement than NIAAA-2Q with AUDIT in detecting unhealthy alcohol drinking among surgical patients. These results suggest that the detection of unhealthy alcohol drinking may be increased by the administration of questions aimed at assessing the weekly average of alcohol intake. The modest time required for NIAAA-4Q administration is a major advantage in clinical practice with respect to AUDIT. Further research will compare NIAAA-2Q and NIAAA-4Q with other brief alcohol screening tests.
- Published
- 2012
21. Alcohol use disorders, and at-risk drinking in patients affected by a mood disorder, in Cagliari, Italy: sensitivity and specificity of different questionnaires
- Author
-
Gian Luigi Gessa, Priamo Marras, Roberta Agabio, and Bernardo Carpiniello
- Subjects
Adult ,Male ,medicine.medical_specialty ,Alcohol Drinking ,Psychometrics ,Prevalence ,Alcohol use disorder ,Sensitivity and Specificity ,Risk Factors ,Surveys and Questionnaires ,medicine ,Humans ,Risk factor ,Psychiatry ,Mood Disorders ,business.industry ,Medical record ,General Medicine ,Middle Aged ,medicine.disease ,CAGE questionnaire ,Mood ,Italy ,Mood disorders ,Diagnosis, Dual (Psychiatry) ,Female ,business ,Alcohol-Related Disorders - Abstract
Aims: (i) To evaluate the prevalence of alcohol use disorders, and at risk-drinking among outpatients admitted to the Division of Psychiatry, University of Cagliari, Italy, for mood disorders, and (ii) to compare the sensitivity and specificity of the questionnaires used. Methods: Fifty-six patients affected by mood disorders answered to the questions of (i) The NIAAA Guide for identification of at-risk drinking, (ii) AUDIT questionnaire, (iii) The CAGE questionnaire and, (iv) SCID-I application forms for mood and alcohol use disorders. Results: Fourteen subjects (25%) met the criteria for alcohol use disorders according to SCID-I; 17 (30.4%) achieved a score ≥ 1 in CAGE questionnaire; 12 (21.4%) reached AUDIT scores of ≥8 and 4 for men and women, respectively; 12 (21.4%) provided positive answers to NIAAA Guide. Despite these prevalence rates, no diagnosis of alcohol use disorders had previously been registered in their medical records. The CAGE questionnaire achieved the highest values of sensitivity and specificity in detecting alcohol use disorders tested against that of the SCID-I. Conclusions: Alcohol use disorders and at-risk drinking are frequent in patients affected by mood disorders, although often underestimated; this underestimation was virtually absolute in the sample of patients investigated. Combination of the CAGE questionnaire plus the first questions in the NIAAA Guide may be an effective tool for use in the identification of psychiatric patients with possible alcohol use disorders or at-risk drinking.
- Published
- 2007
22. [GABAB receptor as therapeutic target for drug addiction: from baclofen to positive allosteric modulators]
- Author
-
Giancarlo Colombo and Roberta Agabio
- Subjects
Agonist ,Baclofen ,medicine.drug_class ,media_common.quotation_subject ,Craving ,Alcohol use disorder ,Pharmacology ,Nicotine ,chemistry.chemical_compound ,Allosteric Regulation ,mental disorders ,medicine ,Animals ,Humans ,Molecular Targeted Therapy ,Amphetamine ,media_common ,Addiction ,General Medicine ,Methamphetamine ,medicine.disease ,Substance Withdrawal Syndrome ,Psychiatry and Mental health ,nervous system ,chemistry ,Anesthesia ,GABA-B Receptor Agonists ,medicine.symptom ,Psychology ,Alcohol-Related Disorders ,medicine.drug - Abstract
Tekst ten podsumowuje dane eksperymentalne i kliniczne wskazujące na potencjał terapeutyczny agonisty receptora GABAB, baklofenu w leczeniu zaburzeń związanych z używaniem alkoholu (AUD) oraz zaburzeń związanych z używaniem substancji psychoaktywnych (SUD). W wielu badaniach przedklinicznych wykazano zdolność baklofenu do zmniejszania picia alkoholu (w tym picia ciągami i nawrotów spożycia alkoholu), instrumentalnego doustnego samopodawania alkoholu, samopodawania dożylnego kokainy, nikotyny, amfetaminy, metamfetaminy, morfiny i heroiny u gryzoni. Niektóre randomizowane, kontrolowane badania kliniczne (RCT) oraz opisy przypadków potwierdzają skuteczność baklofenu w zakresie hamowania spożycia alkoholu, odczuwania głodu alkoholu oraz symptomatologii zespołu abstynencyjnego u pacjentów uzależnionych od alkoholu. Dane z badań z randomizacją i badań otwartych oceniających skuteczność baklofenu w SUD są mniej jednoznaczne. Ostatnio pojawiło się zainteresowanie podawaniem wysokich dawek baklofenu u pacjentów z AUD i SUD. Badania przedkliniczne pozwoliły ustalić, że "antyuzależniające" właściwości baklofenu są również cechą pozytywnych allosterycznych modulatorów receptora GABAB (PAM GABAB). W świetle ich bardziej korzystnego profilu działań niepożądanych (w stosunku do baklofenu), PAM GABAB mogą stanowić istotny krok naprzód w farmakoterapii AUD i SUD opartej o ligandy receptora GABAB.
- Published
- 2015
23. Baclofen: a new drug for the treatment of alcohol dependence
- Author
-
Giovanni Gasbarrini, Giovanni Addolorato, Giancarlo Colombo, Lorenzo Leggio, and Roberta Agabio
- Subjects
Delirium tremens ,medicine.drug_class ,business.industry ,Alcohol dependence ,Muscle relaxant ,Craving ,General Medicine ,Pharmacology ,Relapse prevention ,medicine.disease ,chemistry.chemical_compound ,Baclofen ,nervous system ,chemistry ,Alcohol withdrawal syndrome ,Anesthesia ,medicine ,medicine.symptom ,business ,Diazepam ,medicine.drug - Abstract
Summary Recent preclinical and clinical studies have suggested that baclofen, the prototypic γ-aminobutyric acid B (GABAB) receptor agonist, is a promising pharmacological compound for use in the treatment of alcohol dependence. In particular, baclofen has been found to suppress symptoms of alcohol withdrawal syndrome with an efficacy comparable with that of the ‘gold standard’ diazepam. Moreover, baclofen has proven effective in the prevention of relapse due to its ability to reduce alcohol intake and craving in alcoholic patients. Baclofen proved to be manageable, producing no significant side effects and displaying no addictive properties. The efficacy of the drug in the management of both alcohol withdrawal syndrome and relapse prevention should entail a vastly simplified pharmacotherapy of alcohol dependence.
- Published
- 2006
24. Risk of thiamine deficiency and Wernicke's encephalopathy after gastrointestinal surgery for cancer
- Author
-
Roberta Agabio, Mauro Giovanni Carta, Laura Saiu, Angelo Restivo, Gian Luigi Gessa, and Anna Maria Giulia Farci
- Subjects
Adult ,Male ,Risk ,medicine.medical_specialty ,Colorectal cancer ,Encephalopathy ,Wernicke's encephalopathy ,03 medical and health sciences ,chemistry.chemical_compound ,Young Adult ,0302 clinical medicine ,Hospital discharge ,Prevalence ,Medicine ,Humans ,Wernicke Encephalopathy ,Gastrointestinal cancer ,Thiamine ,Young adult ,Thiamine deficiency ,Digestive System Surgical Procedures ,Aged ,Gastrointestinal Neoplasms ,business.industry ,Cancer ,Middle Aged ,medicine.disease ,Surgery ,Alcoholism ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Dietary Supplements ,Female ,business ,030217 neurology & neurosurgery - Abstract
Cancer patients submitted to gastrointestinal surgery are at risk of thiamine deficiency (TD) and Wernicke's encephalopathy (WE). Although permanent neurological damage and death could be prevented by a timely replacement therapy, they often remain undiagnosed and untreated. We hypothesized that WE remains unrecognized because most cases may manifest several months after hospital discharge.WE frequency was investigated in a sample of cancer patients who underwent gastrointestinal surgery, by using the diagnostic criteria proposed to improve diagnosis among alcoholics. Patients were evaluated at discharge through the examination of medical records and 6 months after by telephonic interview.Forty-five patients were selected. Signs of WE resulted in 4.4% at discharge. At 6 months, 21 patients were interviewed. Among them, 90.4% had signs of WE. The number of affected patients was significantly higher 6 months after discharge than at discharge (90.4 vs 9.5%, p 0.0001).Further studies with larger samples are needed to establish the prevalence of TD and related WE in cancer patients after gastrointestinal surgery. This study suggests that the problem is understated. Even in absence of symptoms of TD, the use of prophylactic thiamine supplementation should be taken in consideration, as consequences of misdiagnosis can be severe.
- Published
- 2014
25. Role of GABAB receptor in alcohol dependence: Reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics
- Author
-
Giovanni Addolorato, Giancarlo Colombo, Gian Luigi Gessa, Fabio Pibiri, Giovanni Vacca, Salvatore Serra, Roberta Agabio, and Mauro A.M. Carai
- Subjects
Baclofen ,Alcohol Drinking ,Pharmacology ,Toxicology ,chemistry.chemical_compound ,Alcohol and health ,medicine ,Animals ,Humans ,Alcohol tolerance ,GABA Agonists ,Clinical Trials as Topic ,Motivation ,Delirium tremens ,Ethanol ,business.industry ,General Neuroscience ,Alcohol dependence ,medicine.disease ,Rats ,Substance Withdrawal Syndrome ,Alcoholism ,Receptors, GABA-B ,nervous system ,chemistry ,Anesthesia ,Alcohol withdrawal syndrome ,business ,Alcohol Abstinence - Abstract
The present paper describes the results of recent preclinical and clinical studies conducted in this laboratory in order to characterize the anti-alcohol properties of the GABA(B) receptor agonist, baclofen. At a preclinical level, the repeated administration of non-sedative doses of baclofen dose-dependently suppressed the acquisition and maintenance of alcohol drinking behavior in selectively bred Sardinian alcohol-preferring (sP) rats tested under the homecage, 2-bottle "alcohol vs water" choice regimen. Acute injection of baclofen completely blocked the temporary increase in voluntary alcohol intake occurring after a period of alcohol abstinence (the so-called alcohol deprivation effect, which models alcohol relapses in human alcoholics). Acute treatment with baclofen also dose-dependently suppressed extinction responding for alcohol (an index of motivation to consume alcohol) in sP rats trained to lever-press for oral alcohol self-administration. Taken together, these results suggest the involvement of the GABA(B) receptor in the neural substrate mediating alcohol intake and alcohol motivational properties in an animal model of excessive alcohol consumption. Further, acutely administered baclofen dose-dependently reduced the severity of alcohol withdrawal signs in Wistar rats made physically dependent upon alcohol. Preliminary clinical surveys suggest that the anti-alcohol properties of baclofen observed in rats may generalize to human alcoholics. Indeed, a double-blind survey demonstrated that repeated daily treatment with baclofen was associated, when compared to placebo, with a higher percentage of subjects totally abstinent from alcohol and a higher number of days of total abstinence. Treatment with baclofen also suppressed the number of daily drinks and decreased the obsessive and compulsive components of alcohol craving. Finally, a single non-sedative dose of baclofen resulted in the rapid disappearance of alcohol withdrawal symptomatology, including delirium tremens, in alcohol-dependent patients. In both clinical studies, baclofen was well tolerated with minimal side effects. These results suggest that baclofen may represent a potentially effective medication in the treatment of alcohol-dependent patients.
- Published
- 2004
26. Rapid suppression of alcohol withdrawal syndrome by baclofen
- Author
-
Esmeralda Capristo, Giancarlo Colombo, Giovanni Addolorato, Gian Luigi Gessa, Giovanni Gasbarrini, Fabio Caputo, Mauro Bernardi, Luigi Janiri, and Roberta Agabio
- Subjects
Adult ,Male ,Baclofen ,media_common.quotation_subject ,Administration, Oral ,Irritability ,NO ,chemistry.chemical_compound ,medicine ,Humans ,Spasticity ,GABA Agonists ,media_common ,Ethanol ,Kindling ,business.industry ,General Medicine ,Middle Aged ,Abstinence ,medicine.disease ,Substance Withdrawal Syndrome ,Treatment Outcome ,Liver ,chemistry ,Alcohol withdrawal syndrome ,Anesthesia ,Delirium ,Female ,medicine.symptom ,business ,Alcohol Abstinence - Abstract
Alcohol withdrawal syndrome is a distressing and at times life-threatening condition in alcohol-dependent patients (1). Usually, symptoms develop within 6 –24 hours after the last drink (2). Early symptoms include raised blood pressure and pulse rate, tremor, hyperreflexia, and anxiety with increased irritability. Clinical management is aimed at symptom relief, prevention of seizures and delirium, and a smooth transition to a treatment program to maintain long-term abstinence from alcohol (3). Benzodiazepines are presently the drug of choice (4). We recently found that baclofen, a -aminobutyric acid (GABA)B receptor agonist used to control spasticity (5), reduced voluntary alcohol intake in alcohol-preferring rats (6), as well as alcohol craving and intake, up to complete alcohol abstinence, in alcohol-dependent patients (7). Furthermore, baclofen suppressed the intensity of alcohol withdrawal syndrome in rats who were physically dependent on alcohol (6). We therefore studied the effects of oral administration of baclofen in patients with severe alcohol withdrawal syndrome.
- Published
- 2002
27. Disulfiram for binge eating disorder: an open trail
- Author
-
Alessandra Chessa, Anna Maria Giulia Farci, Roberta Agabio, Angelo Restivo, Gian Luigi Gessa, S. Piras, and Magnolia Murgia
- Subjects
Adult ,Male ,medicine.medical_specialty ,Nausea ,Craving ,Binge-eating disorder ,Internal medicine ,Appetite Depressants ,Disulfiram ,medicine ,Humans ,Psychiatry ,Binge eating ,Middle Aged ,medicine.disease ,Mean frequency ,Dysgeusia ,Psychiatry and Mental health ,Clinical Psychology ,Treatment Outcome ,Tolerability ,Female ,medicine.symptom ,Psychology ,Binge-Eating Disorder ,medicine.drug - Abstract
To evaluate the efficacy and safety of disulfiram for treatment of binge eating disorder.Two hundred and fifty milligrams per day of disulfiram was administered to 12 patients affected by binge eating disorder for 16 weeks; the number of binge eating episodes per week and the number of participants who reported side effects were evaluated.Nine participants (75.0%) completed the trial, while the other 3 (25.0%) discontinued prematurely. Disulfiram significantly decreased the mean frequency of binge eating episodes per week from 7.9±1.2 to 0.9±0.6 (p.001). All patients (100.0%) reduced the frequency of binge eating episodes, and 7 participants (58.3%) achieved remission of binge eating. Eleven participants (91.7%) reported side effects [drowsiness (N=9), headache (N=7), dysgeusia (N=3), tachycardia (N=3), dizziness (N=2), and nausea (N=2)].While disulfiram reduced the frequency of binge eating episodes, side effects were observed in the majority of participants. Longer-term placebo-controlled studies are warranted to exclude the contribution of a placebo response from these results and to evaluate drugs with similar pharmacological activity but improved tolerability.
- Published
- 2014
28. GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence
- Author
-
Roberta Agabio and Giancarlo Colombo
- Subjects
Agonist ,medicine.drug_class ,Allosteric regulation ,baclofen ,Craving ,Alcohol ,Alcohol use disorder ,Review Article ,Pharmacology ,GABAB receptor ,positive allosteric modulators ,alcohol use disorder ,lcsh:RC321-571 ,chemistry.chemical_compound ,Therapeutic index ,medicine ,animal models of alcohol use disorder ,lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry ,business.industry ,General Neuroscience ,medicine.disease ,Baclofen ,chemistry ,nervous system ,medicine.symptom ,business - Abstract
The present paper summarizes the preclinical and clinical studies conducted to define the “anti-alcohol” pharmacological profile of the prototypic GABAB receptor agonist, baclofen, and its therapeutic potential for treatment of alcohol use disorder (AUD). Numerous studies have reported baclofen-induced suppression of alcohol drinking (including relapse- and binge-like drinking) and alcohol reinforcing, motivational, stimulating, and rewarding properties in rodents and monkeys. The majority of clinical surveys conducted to date – including case reports, retrospective chart reviews, and randomized placebo-controlled studies – suggest the ability of baclofen to suppress alcohol consumption, craving for alcohol, and alcohol withdrawal symptomatology in alcohol-dependent patients. The recent identification of a positive allosteric modulatory binding site, together with the synthesis of in vivo effective ligands, represents a novel, and likely more favorable, option for pharmacological manipulations of the GABAB receptor. Accordingly, data collected to date suggest that positive allosteric modulators of the GABAB receptor reproduce several “anti-alcohol” effects of baclofen and display a higher therapeutic index (with larger separation – in terms of doses – between “anti-alcohol” effects and sedation).
- Published
- 2014
29. Novel pharmacotherapies and patents for alcohol abuse and alcoholism 1998-2001
- Author
-
Roberta Agabio, Mauro A. M. Carai, Giancarlo Colombo, and Gian Luigi Gessa
- Subjects
Pharmacology ,medicine.medical_specialty ,business.industry ,media_common.quotation_subject ,Patent literature ,Alcohol dependence ,Alcohol abuse ,General Medicine ,Abstinence ,medicine.disease ,Pharmacotherapy ,Neurochemical ,New medications ,Drug Discovery ,Medicine ,business ,Psychiatry ,media_common - Abstract
Alcohol abuse and alcoholism are major medical and social problems worldwide. Unfortunately, pharmacotherapies currently available to physicians do not appear to possess relevant therapeutic efficacy. New medications are needed for the enhancing of abstinence and preventing relapse in alcoholics, as well as for reducing alcohol drinking. Relevant improvements in the pharmacotherapy of alcoholism are conceived to derive from elucidation of the elusive mechanisms of alcohol action in brain. Indeed, only a complete knowledge of how alcohol acts in brain and why drinking is so pleasurable and compelling in some individuals will allow the rational design and development of selective drugs capable of correcting the neurochemical alterations underlying alcohol dependence. The present paper reviews the research advances, at both preclinical and clinical levels, published in the scientific literature as well as the most recent (1998-2001) patent literature.
- Published
- 2001
30. Efficacy and tolerability of baclofen in substance use disorders: A systematic review
- Author
-
Gian Luigi Gessa, Antonio Preti, and Roberta Agabio
- Subjects
Drug ,medicine.medical_specialty ,Baclofen ,Health (social science) ,Substance-Related Disorders ,media_common.quotation_subject ,Medicine (miscellaneous) ,macromolecular substances ,Alcohol ,Substance use disorders ,Withdrawal ,chemistry.chemical_compound ,Internal medicine ,medicine ,Humans ,Spasticity ,media_common ,Randomized Controlled Trials as Topic ,business.industry ,organic chemicals ,musculoskeletal, neural, and ocular physiology ,medicine.disease ,Substance Withdrawal Syndrome ,body regions ,Substance abuse ,Psychiatry and Mental health ,Treatment Outcome ,nervous system ,chemistry ,Tolerability ,GABA-B Receptor Agonists ,Substance use ,medicine.symptom ,business - Abstract
Background: It has been reported that baclofen, a drug used in the treatment of spasticity, reduces the severity of withdrawal symptoms and substance use disorders (SUDs) for some psychoactive drugs. Aims and Methods: To evaluate the effectiveness and safety of baclofen in the treatment of withdrawal syndrome and/or SUDs, providing (1) an outline of its pharmacological features; (2) a summary of studies that have suggested its possible effectiveness in the treatment of SUDs, and (3) a review of randomized, controlled trials (RCTs) on baclofen and SUDs. Results: Baclofen tolerability is generally considered to be good. Eleven RCTs investigated its effectiveness in the treatment of SUDs. Of these, 5 RCTs found that baclofen is effective, 5 RCTs found that it is ineffective and the results of 1 RCT were not appreciable because it did not achieve the preplanned level of participation. Conclusions: The number of RCTs on baclofen and SUDs is still low, and their results are divergent. Further RCTs should be undertaken, particularly with higher doses of baclofen. Its administration may be suggested in patients who fail to respond to other approved drugs or who are affected by liver disease that prevents their administration, or in patients affected by SUDs for which no approved drugs are available. Treatment should be conducted under strict medical supervision.
- Published
- 2013
31. γ-Hydroxybutyric Acid (GHB)
- Author
-
G.L. Gessa, Roberta Agabio, Giancarlo Colombo, and M.A.M. Carai
- Subjects
NCS-382 ,GHB receptor ,Pharmacology ,GABAB receptor ,medicine.disease ,Euphoriant ,chemistry.chemical_compound ,Baclofen ,γ-Hydroxybutyric acid ,chemistry ,medicine ,Neurotransmitter ,Psychology ,Narcolepsy - Abstract
γ-Hydroxybutyric acid (GHB) is a naturally occurring constituent of the mammalian brain, where it likely functions as neurotransmitter or neuromodulator. When exogenously administered, GHB exerts a variety of psychopharmacological effects, including euphoria, anxiolysis, sedation, and anesthesia. Most of these effects appear to be mediated by activation of the GABAB receptor, although a GHB-specific binding site has also been described. Applications of GHB in the treatment of narcolepsy and alcoholism have been proposed. Recreational use of GHB, often leading to cases of intoxication, dependence and withdrawal, has dramatically spread over the past 20 years.
- Published
- 2010
32. Alcohol use disorders in primary care patients in Cagliari, Italy
- Author
-
Manuela Nioi, Paolo Valle, Claudia Serra, Gian Luigi Gessa, and Roberta Agabio
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Primary health care ,MEDLINE ,Alcohol ,Alcohol use disorder ,Primary care ,Audit ,chemistry.chemical_compound ,Physicians ,Surveys and Questionnaires ,medicine ,Humans ,Aged ,Alcohol Use Disorders Identification Test ,Primary Health Care ,business.industry ,Data Collection ,General Medicine ,Middle Aged ,medicine.disease ,Alcohol use test ,Alcoholism ,chemistry ,Italy ,Family medicine ,Female ,business - Abstract
Aims: To evaluate the number of subjects with possible alcohol use disorders (SPAUD) among primary care patients in Cagliari, Sardinia, Italy, by means of the self-administration of Alcohol use disorder identification test (AUDIT) and CAGE questionnaires. Methods: 939 patients waiting in 10 surgeries of primary care physicians were asked to take part in the study. A sample of 309 women and 197 men (total 506), aged between 18 and 65 years, agreed to participate and completed both questionnaires. SPAUD were defined as those achieving cut-off scores of 5 for AUDIT and/or 1 for CAGE. Results: Seventy-nine (15.61%) patients were SPAUD, achieving a positive score in at least one questionnaire. Fifty-six (11.07%) and forty-six (9.09%) patients yielded positive results with AUDIT and CAGE, respectively. Twenty-three (4.55%) patients were positive at both AUDIT and CAGE. Significantly higher proportions of men than women were recorded among SPAUD.Conclusions:The results of the present survey indicate a high number of SPAUD in a sample of primary care settings in Cagliari, closely similar to the occurrence of alcohol use disorders estimated in several other community-based primary care clinics in Western Countries.
- Published
- 2006
33. Baclofen: clinical data
- Author
-
Giovanni Addolorato, L Leggio, Gian Luigi Gessa, Giovanni Gasbarrini, Giosue DeLorenzi, Ludovico Abenavoli, Roberta Agabio, Fabio Caputo, Anna Ferrulli, Giancarlo Colombo, SPANAGEL R. MANN K., Addolorato G., Abenavoli L., Leggio L., De Lorenzo G., Ferrulli A., Caputo F, Agabio R, Gessa G.L., Colombo G, and Gasbarrini G.
- Subjects
WITHDRAWAL SYNDROME ,Delirium tremens ,business.industry ,musculoskeletal, neural, and ocular physiology ,RELAPSE ,medicine.disease ,BACLOFEN ,humanities ,NEUROPHARMACOLOGY ,NO ,Cocaine dependence ,body regions ,Ventral tegmental area ,chemistry.chemical_compound ,medicine.anatomical_structure ,Baclofen ,nervous system ,chemistry ,Alcohol withdrawal syndrome ,Anesthesia ,Medicine ,ALCOHOLISM ,business ,health care economics and organizations ,Alcohol Abstinence - Abstract
This chapter describes the clincial experience related to the use of Baclofen as a pharmacological treatment of alcohol withdrawal syndrome.
- Published
- 2006
34. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam
- Author
-
Roberta Agabio, Lorenzo Leggio, Fabio Caputo, Gian Luigi Gessa, Ludovico Abenavoli, Esmeralda Capristo, Giovanni Gasbarrini, Giovanni Addolorato, Giancarlo Colombo, Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, Colombo G, Gessa GL, and Gasbarrini G.
- Subjects
Adult ,Male ,Baclofen ,medicine.drug_class ,Alcohol withdrawal syndrome, CIWA-AR, baclofen, diazepam ,ALCOHOL WITHDRAWAL SYNDROME ,CIWA-AR ,Severity of Illness Index ,NO ,chemistry.chemical_compound ,medicine ,Humans ,GABA Agonists ,Aged ,Benzodiazepine ,Diazepam ,Ethanol ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Substance Withdrawal Syndrome ,Tolerability ,chemistry ,Anti-Anxiety Agents ,Anesthesia ,Alcohol withdrawal syndrome ,Anxiety score ,Anxiety ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
Purpose Benzodiazepines are the drugs of choice in the treatment of alcohol withdrawal syndrome (AWS). Recent data have shown that baclofen may reduce AWS symptoms. At present, no comparative studies between baclofen and any benzodiazepine used in AWS treatment are available. Accordingly, the present study was designed to compare efficacy, tolerability and safety of baclofen versus diazepam in the treatment of AWS. Subjects and methods Thirty-seven patients with AWS were enrolled in the study and randomly divided into 2 groups. Baclofen (30 mg/day for 10 consecutive days) was orally administered to 18 patients (15 males, 3 females; median age: 46.5 years). Diazepam (0.5-0.75 mg/kg/day for 6 consecutive days, tapering the dose by 25% daily from day 7 to day 10) was orally administered to 19 patients (17 men, 2 women; median age: 42.0 years). The Clinical Institute Withdrawal Assessment (CIWA-Ar) was used to evaluate physical symptoms of AWS. Results Both baclofen and diazepam significantly decreased CIWA-Ar score, without significant differences between the 2 treatments. When CIWA-Ar subscales for sweating, tremors, anxiety and agitation were evaluated singly, treatment with baclofen and diazepam resulted in a significant decrease in sweating, tremors and anxiety score, without significant differences between the 2 drug treatments. Both treatments decreased the agitation score, although diazepam was slightly more rapid than baclofen. Conclusion The efficacy of baclofen in treatment of uncomplicated AWS is comparable to that of the "gold standard" diazepam. These results suggest that baclofen may be considered as a new drug for treatment of uncomplicated AWS.
- Published
- 2005
35. Development of short-lasting alcohol deprivation effect in sardinian alcohol-preferring rats
- Author
-
Carla Lobina, Giancarlo Colombo, Roberta Reali, Marialaura Pani, Mauro A.M. Carai, Roberta Agabio, Giovanni Vacca, and Gian Luigi Gessa
- Subjects
Male ,medicine.medical_specialty ,Health (social science) ,Alcohol Drinking ,media_common.quotation_subject ,Temperance ,Alcohol ,Toxicology ,Biochemistry ,Behavioral Neuroscience ,chemistry.chemical_compound ,Internal medicine ,medicine ,Animals ,media_common ,Ethanol ,business.industry ,Central Nervous System Depressants ,General Medicine ,Abstinence ,Alcohol preferring ,medicine.disease ,Privation ,Surgery ,Rats ,Endocrinology ,Neurology ,chemistry ,Toxicity ,Alcohol intake ,business ,Alcohol Abstinence - Abstract
Alcohol deprivation effect (ADE), defined as a temporary increase in voluntary alcohol intake following a period of alcohol abstinence, was evaluated in selectively bred Sardinian alcohol-preferring (sP) rats. Alcohol was initially offered in free choice with water for 35 consecutive days (predeprivation phase). Subsequently, one group of rats was deprived of alcohol for 1, 3, 7, 15, 30, 90 or 180 consecutive days, while the second group had continuous access to alcohol (deprivation phase). Once alcohol was re-presented, alcohol intake in alcohol-deprived rats was recorded 1 and 24 h after alcohol re-presentation and compared to that monitored in alcohol-nondeprived rats over the same time periods (postdeprivation phase). Alcohol deprivation for 3 to 30 days resulted in a significant increase in voluntary alcohol intake only in the first hour of re-access. These results demonstrate the development of ADE in sP rats. However, the rapid return of alcohol intake to control levels is discussed as evidence in favor of a set-point mechanism capable of regulating alcohol-drinking behavior in sP rats.
- Published
- 2000
36. THIAMINE ADMINISTRATION IN ALCOHOL-DEPENDENT PATIENTS
- Author
-
Roberta Agabio
- Subjects
Vitamin ,Coma ,medicine.medical_specialty ,Pediatrics ,Obtundation ,Ataxia ,business.industry ,Encephalopathy ,Thiamine Deficiency ,General Medicine ,medicine.disease ,Surgery ,Ocular Motility Disorders ,Alcoholism ,chemistry.chemical_compound ,chemistry ,medicine ,Humans ,Thiamine ,medicine.symptom ,business ,Clouding of consciousness - Abstract
( Received 28 August 2004; first review notified 12 September 2004; in revised form 28 September 2004; accepted 7 October 2004 ) Thiamine (vitamin B1) is a water-soluble vitamin that is involved in the metabolism of glucose and lipids as well as in the production of glucose-derived neurotransmitters (see Cook et al ., 1998). Its deficiency leads to a variety of neurological and cardiovascular symptoms and signs. Early symptoms may include fatigue, weakness and emotional disturbance, whereas prolonged gradual deficiency may lead to a form of polyneuritis (known as dry beriberi), cardiac failure or peripheral oedema (wet beriberi) (Thomson, 2000). Severe thiamine deficiency (TD) may result in the development of Wernicke's encephalopathy (WE). The classical signs of WE are ocular motility disorders (nystagmus, ophthalmoplegia), ataxia and mental changes (confusion, drowsiness, obtundation, clouding of consciousness, pre-coma and coma), although minor episodes of 'subclinical' encephalopathies are frequent (Reuler et al ., 1985). An appropriate treatment may correct most of these abnormalities; in contrast, the lack of a diagnosis of WE may result in serious consequences (Reuler et al ., 1985 …
- Published
- 2004
37. Baclofen in the treatment of alcohol withdrawal syndrome: A randomized comparative study versus diazepam
- Author
-
Anna Ferrulli, Gl Gessa, Giovanni Addolorato, Roberta Agabio, Giancarlo Colombo, F. Caputo, L. Vonghia, Cristina D'Angelo, Giuseppe Francesco Stefanini, S. Cardone, G. Gasbarrini, Lorenzo Leggio, Noemi Malandrino, Mauro Bernardi, Ludovico Abenavoli, Esmeralda Capristo, and Antonio Mirijello
- Subjects
chemistry.chemical_compound ,Baclofen ,Hepatology ,chemistry ,business.industry ,Alcohol withdrawal syndrome ,Anesthesia ,Gastroenterology ,medicine ,medicine.disease ,business ,Diazepam ,medicine.drug - Published
- 2006
38. 11 OC Rapid suppression alcohol withdrawal syndrome by administration of baclofen
- Author
-
Marco Domenicali, Giovanni Gasbarrini, Giovanni Addolorato, Giuseppe Francesco Stefanini, G. De Lorenzi, Gl Gessa, Mauro Bernardi, Roberta Agabio, R. Mascianà, Giancarlo Colombo, F. Lorenzini, F. Caputo, and C. Ancona
- Subjects
chemistry.chemical_compound ,Baclofen ,Hepatology ,chemistry ,business.industry ,Kindling ,Alcohol withdrawal syndrome ,Anesthesia ,Gastroenterology ,Medicine ,business ,medicine.disease ,Administration (government) - Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.